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maintained within PDA-defined limits). Simulations were conducted in CORE dia-
betes model, which is a Markov model built on the base of published clinical trials
and encompasses over a dozen of diabetes complications. The model was exten-
sively validated and allows for reliable estimation of costs and outcomes associ-
ated with diabetes. Model inputs were adapted to Polish setting. Economic analysis
was conducted in lifetime horizon, costs and outcomes were discounted (5% and
3,5%, respectively). Cost acceptability threshold in Poland is 25 511 euro per QALY
gained. RESULTS: John’s QALY is 0,3 lower that QALY of Peter. Treatment of John’s
complications is 400 euro more expensive as compared to Peter. If willingness to
pay (WTP) equals to €7500 euro per QALY, yearly costs of Peter’s treatment may be
250 euro higher that John’s. If WTP is €15,000, Peter’s treatment may be €450 more
expensive that John’s and if WTP is €25,000 the difference in treatment costs may
be as high as 725 euro. CONCLUSIONS:DM2 treatment along with PDA recommen-
dations may be cost-effective provided additional costs do not exceed €725 per
year.
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INTRODUCTION: Good T2DM management requires not only good control of blood
glucose, but also blood pressure and serum lipid levels. Although data from the
Swedish National Diabetes Registry indicates that more patients have attained
recommended levels of these biomarkers over time, a sizable proportion fails to
meet all of these goals. OBJECTIVES: Assess the cost-effectiveness of intensifying
therapy to achieve Swedish-specific treatment goals for HbA1c, systolic blood pres-
sure (SBP), and LDL versus usual care for patients newly diagnosed with T2DM and
younger than fifty. METHODS: We used the Economic and Health Outcomes
(ECHO)-T2DM model, a Markov-based micro-simulation model, to simulate the
lifetimes of 500 cohorts of 500 hypothetical patients under two different scenarios:
1) treatment to maintain target goals for HbA1c, SBP and LDL; and 2) treatment to
maintain levels observed empirically in Sweden. Pharmacotherapy treatment
pathways for the control of hyperglycemia, hypertension and dyslipidemia fol-
lowed Swedish guidelines and were identical in the two scenarios. The costs of
pharmacotherapy and medical events were obtained from Swedish data.RESULTS:
Treatment to HbA1c, SBP and LDL goals versus treatment to observed levels in
Sweden resulted in a small QALY gain (0.13) and medical cost-savings of SEK
3552(€395). Spending on glucose-lowering agents, anti-hypertensives, and lipid-
lowering agents was increased by SEK 4136(€460), SEK 4864(€540) and SEK
2390(€265), respectively. Costs due to micro- and macrovascular complications
were reduced by SEK 5731(€637) and SEK 9522(€1058), respectively. CONCLUSIONS:
For patients newly diagnosed with T2DM and younger than fifty in Sweden, inten-
sifying therapy to maintain target glucose, blood pressure, and lipid levels resulted
in increased spending on pharmacotherapy, however, spending on micro- and
macrovascular events was reduced by a greater degree. These results suggest that
allocating more resources toward the attainment of these goals may be welfare-
improving.
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OBJECTIVES: To compare the cost-effectiveness of Follitropin Alpha (Gonal-F®),
which is a recombinant FSH, with a urinary highly purified hp-FSH (Menopur®)
used in assisted reproduction in Greece.METHODS:A decision tree in combination
with a Markov model was constructed to assess the clinical and economical impact
of comparators for three consecutives cycles. Transition probabilities for all stages
of a treatment cycle (i.e, cancelled ovum retrieval, successful recovery of oocytes
etc) were derived from literature and validated by clinical experts. Cost compo-
nents such as “initial treatment cost”, cost of “oocytes”, “oocyte pick-up”, “fertil-
ization”, “transfer”, “cryo preservation” and “frozen- thawed embryo transfer
(FET)” were derived from the electronic databases of selected private and public
clinics. The average number of units used per IVF and the rate of adverse events
were based on the literature. Drug prices and reimbursement tariffs, were obtained
from the “Government Gazette” and valued at 2011 prices. A probabilistic sensitiv-
ity analysis was performed to deal with uncertainty and to construct variability
measures. RESULTS: There was a statistically significant difference in favor of the
r-FSH arm compared to hp-HMG, which is associated with 52 more life births
(95%CI: 26-78, p-value0.001) per 1,000 patients. The cost per life birth was esti-
mated at €16,906 (95%CI: €16,347 – €17,516) and €17,286 (95%CI: €16,740 – €17,845) in
the r-FSH and hp-HMG arms, respectively. The cost per IVF was estimated at €4,365
(95%CI: €4,205 – €4,506) in the r-FSH and €3,815 (95%CI: €3,661 – €3,953) in hp-HMG
arm, indicating a difference at €550 (95%CI: €365 – €730, p-value0.001). The incre-
mental cost per life birth (ICER) for r-FSH versus hp-HMG was estimated at €14,540
(95%CI: €10,509 – €21,868), while the incremental cost per life year was estimated at
€4,153 (95%CI: €2,038 – €6,233). CONCLUSIONS: r-FSH may represent a cost-effec-
tive choice compared with a urinary hp-FSH (Menopur®) used for ovarian stimu-
lation in the Greek setting.
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OBJECTIVES: This study estimated the effect of weight reduction on long-term
outcomes and associated direct medical costs for patients newly diagnosed with
T2DM and less than fifty years old in Sweden. METHODS: We simulated the life-
times of 500 cohorts of 1000 patients with characteristics based on the Swedish
National Diabetes Register using the Economic and Health Outcomes (ECHO)-T2DM
model. All patients were assumed to increase weight over time (0.23 kg per year)
however, half of the patients were assumed to lose 5 kg in the first year, so that a 5
kg differential was maintained. The effect of weight on T2DM complications was
modeled using risk equations from the UK Prospective Diabetes Study, wherein
weight is only a direct determinant of the risk of congestive heart failure (CHF). The
risks of stroke and myocardial infarction are affected only indirectly via their link-
age with CHF, and mortality risk is affected only indirectly via macrovascular event
history. Weight change was assumed to impact QALYs by an amount reported in
the T2DM-specific CODE-2 study. Pharmacotherapy was administered according to
Swedish recommendations and Swedish cost data was used for medical events and
pharmacotherapy. RESULTS: A weight loss of 5 kg resulted in cost-savings of SEK
654 (€69) over an average of 17.1 years, mainly attributable to reductions in CHF
incidence. Life years increased marginally; QALYs, however, increased more sub-
stantially (0.18). CONCLUSIONS: At a relatively conservative willingness-to-pay
threshold of SEK 250,000 (€26,540), an intervention that resulted in a one-time
weight loss of 5 kg would be welfare improving at a cost of up to SEK 45,654 (€4,846)
over 17.1 years. As this simulation conservatively excluded a number of other
benefits of weight loss (e.g., effects via improved lipids, blood pressure and reduc-
tions in other weight-related illnesses), the true economic value is likely greater.
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OBJECTIVES: The aim of this economic evaluation was to test the hypothesis that
the clinical benefits observed with pioglitazone in the PROactive Study will lead to
economic benefits in terms of reduced macrovascular complications costs and
insulin treatment in Italy (the trial compared standard of care  pioglitazone ver-
sus standard of care alone).METHODS:Two analyses were undertaken; within trial
analysis and life-time simulation. The PROactive study provided the clinical and
resource utilization data to estimate the cost-effectiveness of pioglitazone in the
within trial analysis and was the basis for the secondary analysis which undertook
a life time simulation using a modified version of the validated CORE diabetes
model. CODE-II utility values were used for the base case. Due to the distribution
system of pioglitazone in Italy, two different prices were used; the public price paid
by the retail market (€2.11 per patient per day) and the ex-factory price discounted
by 25% (€ 0.96 per patient per day). Costs and health gains were discounted at the
joint rate of 3%. RESULTS: The incremental utility gain in within trial analyses was
0.0191, the incremental event and medication costs in the public price scenario
were €842 leading to an ICER of €43,996 per QALY. In the lifetime simulation model
the incremental utility gain was 0.149, the incremental event and medication costs
in the public price scenario were €3,783 leading to an ICER of €25,426 per QALY. In
the ex-factory price discounted by 25% scenario the medication costs were lower
leading to the inclusion of pioglitazone in treatment being dominant in both
analyses. CONCLUSIONS: In the Italian setting reduced costs for macrovascular
complications and insulin treatment leads to the inclusion of pioglitazone in treat-
ment being within standard cost-utility thresholds and is therefore an effective use
of health resources.
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OBJECTIVES: To estimate the long-term cost-effectiveness of transferring type 2
diabetes patients to an insulin detemir regimen therapy from a Neutral Protamine
Hagedorn (NPH) insulin regimen in the Portuguese routine clinical practice.
METHODS: A computer simulation model “CORE Diabetes Model” was used to
make long-term projections of clinical outcomes and direct medical costs based on
short term findings from the European cohort in the PREDICTIVE trial. Therapy
conversion to insulin detemir was associated with a reduction in glycosylated
haemoglobin (HbA1c) by 0.2% (p  0.05), mean body weight was reduced by 0.7 kg
(p0.01) and the incidence of total hypoglycaemia decreased from 11.7 to 3.0 epi-
sodes per patient/year (p  0.0001). Events were projected for a time horizon of 30
years. The cost analysis takes the perspective of the Portuguese National Health
System. RESULTS: Therapy conversion to insulin detemir plus OADs improves life
expectancy by 0.056 years and quality-adjusted life years (QALY) by 0.462 com-
pared to NPH insulin plus OAD. The incremental cost effectiveness ratio cost per
life years gained and per QALY gained with insulin detemir plus OADs treatment as
compared to NPH insulin plus OADs is 3,239€ and 393€ respectively. Type 2 diabetes
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complications treatment costs were the main cost driver, accounting for 67% and
77% of total direct costs of the insulin detemir therapy and NPH insulin therapy
respectively. Due to a better reduction from baseline of HbA1c the development and
progression of complications was delayed, and the cumulative incidence of diabe-
tes complications decreased for insulin detemir plus OADs therapy versus NPH
insulin plus OADs therapy. CONCLUSIONS: The results of this study demonstrate
that insulin detemir is a very cost-effective option for the treatment of type 2
diabetes compared to NPH insulin in Portugal.
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OBJECTIVES: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in
Europe and the USA. Angiotensin-converting enzyme (ACE) inhibitors slow down
the progression of renal disease and therefore provide a renal-protective effect.
The aim of our study was to assess the most cost-effective time to start an ACE
inhibitor (or an angiotensin II receptor blocker (ARB) if coughing as a side effect
occurs) in patients with newly diagnosed type 2 diabetes in the The Netherlands.
METHODS: Three strategies were compared: treating all patients at the time of
diagnosing type 2 diabetes, screening for microalbuminuria, and screening for
macroalbuminuria. A lifetime Markov decision model with simulated 50-year-old
patients with newly diagnosed diabetes mellitus was developed using published
data on costs and health outcomes and simulating the progression of renal disease.
A health insurance perspective was adopted. RESULTS: In the base-case analysis,
the treat-all strategy is associated with the lowest costs and highest benefit and
therefore dominates screening both for macroalbuminuria and microalbuminuria.
A multivariate sensitivity analysis shows that the probability of savings is 70%.
Treating all patients with an ARB would also be a dominant strategy despite the
fact that ARBs are a much more expensive alternative. CONCLUSIONS: Patients
with type 2 diabetes should receive an ACE inhibitor immediately after diagnosis if
they do not have contraindications. An ARB should be considered for those patients
developing a dry cough under ACE inhibitor therapy. The potential for cost savings
would be even larger if the prevention of cardiovascular events were considered.
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OBJECTIVES: The UK Prospective Diabetes Study (UKPDS) reported a persistence in
risk reduction of diabetes-related events associated with improved glycaemic con-
trol observed between intensive and conventional therapy groups beyond the in-
tervention period. This has important implications for projecting short-term clin-
ical trial results over long-term time horizons. The aim of this study was to
reproduce the UKPDS legacy effect and assess the impact on long-term
cost-effectiveness. METHODS: The Cardiff Type 2 Diabetes Model was initiated
with cohort profiles consistent with reported intensive versus conventional control
groups within UKPDS; initial HbA1c treatment effects were applied and modelled
over time assuming two scenarios: a loss of antihyperglycaemia benefit at year 10
or maintenance of clinical benefit (the legacy effect). Under both scenarios, risk
reductions and cost-effectiveness of sulphonylurea (SU) versus insulin were as-
sessed over a 40-year time horizon using UK 2010 costs. Both costs and health
benefits were discounted at 3.5%. RESULTS: The risk ratio (RR) of any diabetes-
related end point predicted by the model was consistent with that reported by
UKPDS when incorporating the legacy effect (RR of 0.90 versus 0.91 in the model
and UKPDS, respectively). Ignoring the legacy effect resulted in a RR of 0.99 at year
30 and a cost per quality-adjusted life-year (QALY) of £162,400, compared with
£22,565 when including the legacy effect. CONCLUSIONS: The legacy effect of in-
tensive glucose-lowering strategies has important implications when assessing
the cost-effectiveness of new therapies. Failure to include such a legacy effect, as
seen in UKPDS, may result in new therapies for managing glycaemic control ap-
pearing less cost-effective than they actually are.
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OBJECTIVES: To estimate short-term cost-effectiveness of insulin detemir versus
Neutral Protamine Hagedorn (NPH) insulin based on incidence of self-treated hy-
poglycaemia and body-weight gain in insulin-naïve subjects with type 2 diabetes in
Sweden. METHODS: A short-term (one year) cost-effectiveness model was devel-
oped in Microsoft Excel® 2003. Hypoglycaemia incidence rates were based on
UKHSG data. Relative risk (RR) of hypoglycaemia, weight change and insulin doses
were obtained from randomized clinical trial data. Resource use (health care con-
tacts, blood glucose tests) and sick-leave following hypoglycaemia were estimated
from survey data. Effectiveness was expressed as quality adjusted life-years
(QALYs). Direct and indirect costs were in Swedish Kronor (SEK 1  €0.10, 2010
values) with unit costs from official sources. Probabilistic sensitivity analyses were
performed. RESULTS: Treatment with detemir was associated with fewer self-
treated hypoglycaemic events compared with NPH (RR: 0.47 [CI 0.25:0.88]) and
lower weight gain (mean difference -0.91 kg [CI -1.53;-0.28]), leading to an average
gain of 0.011 QALYs per year. Annual costs were SEK6,505 for detemir versus
SEK5,008 for NPH with an incremental cost-effectiveness ratio (ICER) of SEK139,665
per QALY gained for detemir versus NPH from a societal perspective. From a health
care perspective, annual costs were SEK5,809 for detemir and SEK3,527 for NPH
with an ICER of SEK212,909 per QALY gained for detemir versus NPH.
CONCLUSIONS: Insulin detemir can be considered cost-effective versus NPH insu-
lin in insulin-naïve subjects with type 2 diabetes in Sweden already in the first year
of treatment, both from a health care and a societal perspective, based on reduc-
tions in self-treated hypoglycemia and superior weight management. Given the
non-significant differences in HbA1c control, results of the short-term analyses is
not expected to deviate substantially if longer time horizons are applied. Higher
pharmacy costs with insulin detemir should not be a barrier to therapy based on
these findings.
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OBJECTIVES: This analysis of CHOICE presents resource use data from the six
months pre and post initiation of adult patients’ first injectable therapy for the
treatment of T2D (ExBID or INS). CHOICE is an ongoing European 6 country pro-
spective observational study. METHODS: Patient data are collected immediately
before (baseline), and 3, 6, 12, 18 and 24 months after, initiation of injectable
therapy. RESULTS: Important baseline differences between the ExBID and INS co-
horts prevent direct comparison of outcome data. In the ExBID cohort (baseline
n1177; 6 months n1073) 78.8% patients self-monitored their blood glucose
(SMBG) at baseline; 81.6% at 6 months. Mean (SD) tests/week (past 4 weeks) were
9.28 (7.93) and 8.24 (6.41) respectively. Mean (SD) number of oral antihyperglycae-
mic medications used was 1.20 (0.75) at baseline and 1.42 (0.73) at 6 months. 93.4%
patients had 1 contact with a health care professional (HCP) in 6 months before
ExBID initiation (mean [SD] 7.75 [7.49] visits); 89.1% in 6 months post initiation (7.55
[7.41]). In the INS cohort (baseline n1315; 6 months n1235), 79.8% patients SMBG
at baseline; 92.4% at 6 months. Mean (SD) tests/week were 9.91 (8.58) and 13.08
(8.46) respectively. Mean (SD) number of oral antihyperglycaemic medications used
was 0.96 (0.76) at baseline and 0.98 (0.77) at 6 months. 93.8% patients had1 contact
with a HCP in 6 months before INS initiation (mean [SD] 8.45 [9.19] visits); 93.2% in
6 months post initiation (11.11 [16.75]). Mean doses of both ExBID and INS increased
during the first 6 months post initiation. In both ExBID and INS cohorts, between-
country variability was found. CONCLUSIONS:Mean resource utilisation increased
following initiation of injectable therapy. Increases in mean test strip use/week
(32%) and mean number of contacts with HCPs (31%) were observed in the INS
cohort. Respective observations for ExBID cohort were -12.7% and -2.7%.
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OBJECTIVES: Hypercortisolism in Cushing’s Disease (CD) is associated with signif-
icant comorbidities, which improve and in some cases are reversed with biochem-
ical control (BC). The purpose of this study was to capture data describing comor-
bidity reductions with BC and estimate the potential cost savings associated with
reversal. METHODS: Comorbidity reductions with BC were identified through a
comprehensive literature search using CD AND epidemiology, morbidity, compli-
cations, BC and treatment outcomes as search terms. Selected clinical studies
detailed the relationship between comorbidity and BC in adults. In the cost analy-
sis, comorbidities were selected if reported in patients achieving BC. Literature-
based cost estimates were identified for CD-related comorbidities from the US
payer perspective, and inflated to 2010 USD. Cost ranges were reported as the
difference between expected comorbidity costs in uncontrolled and controlled pa-
tients. Sensitivity analyses were conducted to also include possibly reversible
comorbidities. RESULTS: Patients with CD experience comorbidities ranging from
back pain (86%) to psychosis (1.4%). Of 16 comorbidities identified in this study,
seven were certainly reversible in CD patients achieving BC. Hypertension and
diabetes mellitus were reversed in 44% and 40% of patients achieving BC at 1 year.
Psychiatric illness and nephrolithiasis were resolved in 76% and 50% of CD pa-
tients. In CD patients with reported impaired glucose tolerance and overweight/
obesity, 60% and 37% of cases were resolved with BC. The application of cost esti-
mates to prevalence of each reversible comorbidity before BC yielded a total per-
patient cost of $19,239-$27,600. With BC, expected comorbidity costs ranged from
$12,448-$18,312, representing a cost savings of $6,790-$9,288. Sensitivity analysis
including possibly reversible comorbidities (like back pain, osteoporosis and ver-
tebral fractures) produced estimated total cost savings of $10,571-$14,806 (incre-
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